Real World Observation Studies help in improving diabetes treatment

EASD Diabetes
SHARE
Facebook
Linkedin

The European Association for the Study of Diabetes (EASD) 53rd Annual Meeting was an ideal platform for Sanofi to showcase our commitment to leadership in diabetes and cardiovascular disease. This year, there was more than 30 contributions related to our portfolio, including abstracts and official scientific sessions and satellite symposia.

 

The increase of a worldwide disease

Diabetes affects more than 420 million people worldwide and represents one of the health community’s toughest challenges. An ageing population and a growth in obesity are leading to an increasing prevalence of the condition.

In Europe, diabetes affects 59.8 million people – a number set to rise to 71.1 million by 2040.

 

Two main forms of diabetes

 

Type 1 diabetes can develop at any age, but it is most common before the age of 40. It occurs when the pancreas is unable to produce natural insulin. Symptoms include excessive urination and regular thirst and hunger, as well as unwanted weight loss and fatigue.

 

Type 2 diabetes has similar symptoms, though it is often less pronounced, often leading to late diagnosis. In Type 2 diabetes, not only is the pancreas unable to produce enough insulin, the body is also unable to react to the insulin it does receive, making it difficult to turn glucose into energy.

 

Both types can be avoided and/or managed with a healthy lifestyle plan and the close monitoring and control of glucose intake.

 

Diabetes requires day-to-day management to control blood sugar levels and can lead to complications such as eye diseases, kidney failures, cardiovascular diseases and limb amputations.

Sanofi is committed to fighting diabetes with continued scientific study and data collection that provide a better understanding of diabetes, its impact on the daily life, and the possible treatment options.

 

A better understanding of the Diabetes disease with real world evidence

 

Sanofi used the EASD congress to present results of its Real World Observation Studies, a program that provides a new insight into diabetes management.

As the name suggests, real world observational studies assess management and treatment of a conditon in a real-world setting.

 

With data collected from within communities, it becomes possible to analyze patient outcomes in real-life settings. Real world studies can work hand-in-hand with clinical trials to determine the ultimate effectiveness of treatments approved for use in a specific population.

Sanofi’s Real World program involves studying diabetes management in almost 200,000 people who are using a basal insulin treatment in the US and Europe.

The information is helping physicians and payers to better understand the impact of hypoglycemia risk.

 

Programs like Sanofi’s real world observation studies can help prevent Diabetes and provide healthcare professionals with the information they need to develop more effective and more personalized diabetes management plans.

 

Choose the topics that interest you, like:
or